Equillium announces leadership and corporate updates

La jolla, calif., oct. 06, 2025 (globe newswire) -- equillium , inc. (nasdaq: eq), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its board of directors (bod) and senior leadership, and other corporate updates.
EQ Ratings Summary
EQ Quant Ranking